BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38803946)

  • 1. Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of
    Hernando-Gozalo M; Rescalvo-Casas C; Seijas-Pereda L; Cuadros-González J; Pérez-Tanoira R
    Heliyon; 2024 May; 10(10):e30742. PubMed ID: 38803946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of
    Dubberke ER; Gerding DN; Kelly CP; Garey KW; Rahav G; Mosley A; Tipping R; Dorr MB
    Open Forum Infect Dis; 2020 Jun; 7(6):ofaa157. PubMed ID: 32523972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
    Nelson RL; Suda KJ; Evans CT
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis.
    Stabholz Y; Paul M
    Clin Microbiol Infect; 2024 Jan; 30(1):51-58. PubMed ID: 37690610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection.
    Whitney L; Nesnas J; Planche T
    Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.
    Turner NA; Warren BG; Gergen-Teague MF; Addison RM; Addison B; Rutala WA; Weber DJ; Sexton DJ; Anderson DJ
    Clin Infect Dis; 2022 Mar; 74(4):648-656. PubMed ID: 34017999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.
    Rao K; Zhao Q; Bell J; Krishnan J; Henig O; Daniel J; Sawaya K; Albin O; Mills JP; Petty LA; Gregg K; Kaul D; Malani AN; Pogue J; Kaye KS
    Clin Infect Dis; 2024 Feb; 78(2):277-282. PubMed ID: 37797310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis.
    Okumura H; Fukushima A; Taieb V; Shoji S; English M
    J Infect Chemother; 2020 Jan; 26(1):43-50. PubMed ID: 31624029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.
    Costa DVS; Pham NVS; Hays RA; Bolick DT; Goldbeck SM; Poulter MD; Hoang SC; Shin JH; Wu M; Warren CA
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0048922. PubMed ID: 35861541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for
    Dubberke ER; Puckett JT; Obi EN; Kamal-Bahl S; Desai K; Stuart B; Doshi JA
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac435. PubMed ID: 36267250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
    van Prehn J; Reigadas E; Vogelzang EH; Bouza E; Hristea A; Guery B; Krutova M; Norén T; Allerberger F; Coia JE; Goorhuis A; van Rossen TM; Ooijevaar RE; Burns K; Scharvik Olesen BR; Tschudin-Sutter S; Wilcox MH; Vehreschild MJGT; Fitzpatrick F; Kuijper EJ;
    Clin Microbiol Infect; 2021 Dec; 27 Suppl 2():S1-S21. PubMed ID: 34678515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
    Gentry CA; Campbell DL; Williams RJ
    Int J Antimicrob Agents; 2021 Mar; 57(3):106282. PubMed ID: 33465458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.
    Al Momani LA; Abughanimeh O; Boonpheng B; Gabriel JG; Young M
    Cureus; 2018 Jun; 10(6):e2778. PubMed ID: 30112254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States.
    Jiang Y; Sarpong EM; Sears P; Obi EN
    Infect Dis Ther; 2022 Feb; 11(1):111-126. PubMed ID: 34292496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
    Okumura H; Ueyama M; Shoji S; English M
    J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which is the Preferred Regimen for Non-Severe
    Kim J; Kim J; Kim B; Pai H
    Infect Chemother; 2022 Jun; 54(2):213-219. PubMed ID: 35706079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European Practice for CDI Treatment.
    Fitzpatrick F; Brennan R; van Prehn J; Skally M; Brady M; Burns K; Rooney C; Wilcox MH
    Adv Exp Med Biol; 2024; 1435():57-84. PubMed ID: 38175471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.
    Burton HE; Mitchell SA; Watt M
    Pharmacoeconomics; 2017 Nov; 35(11):1123-1140. PubMed ID: 28875314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.